






To the Editor: Diversity of 
genotypes among Pneumocystis 
jirovecii (human-specifi c Pneumo-
cystis species) isolates mainly involves 
internal transcribed spacer (ITS) 
loci (1). Type Eg, one of the most 
frequently detected ITS genotypes, has 
been found worldwide (2). The locus 
of dihydropteroate synthase (DHPS) 
is also of interest because DHPS is the 
target of sulfonamides, the main drugs 
used to treat Pneumocystis pneumonia 
(PCP). Studies of the DHPS locus 
have found mutations at positions 
165 and 171, which confer potentially 
lower sensitivity to sulfonamides to 
mutant P. jirovecii organisms (3).
Airborne transmission of 
Pneumocystis ssp. has been 
demonstrated among animals and 
probably occurs among humans (4). 
Reports of clusters of PCP cases in 
hospitals (4,5) provide a rationale 
for considering the possibility of 
nosocomial P. jirovecii infections. 
Moreover, we recently quantifi ed P. 
jirovecii in the air surrounding patients 
with PCP (6). Our fi ndings suggested 
that the fungus is exhaled from 
infected patients and then spreads into 
their surrounding air. 
Because matches of P. jirovecii 
genotypes between pulmonary and 
air samples would strengthen these 
fi ndings, we conducted DHPS and 
ITS typing of P. jirovecii isolates from 
PCP patients and from the air in their 
close environment. We assayed P. 
jirovecii DNA that we had previously 
detected in pulmonary samples 
(bronchoalveolar lavage and induced 
sputum) from 15 PCP patients and in 
15 air samples collected 1 meter from 
each patient’s head (6).
ITS genotyping was based on 
sequence analysis of ITS 1 and 2 
regions after amplifi cation with a 
nested PCR, cloning, and sequencing, 
as described (7). ITS alleles were 
identifi ed by using the typing system 
by Lee et al. (2). DHPS genotyping 
was based on a PCR restriction 
fragment-length polymorphism assay 
that enables detection of mutations at 
positions 165 and 171, as described (8).
Among the 15 pulmonary samples, 
ITS genotyping was successful for all 
15; among these, 8 ITS genotypes 
were identifi ed (Table). Type Eg was 
most frequently identifi ed. Mixed 
infections, which correspond to 
detection of >1 genotype in a given 
sample, were detected in 5 samples. 
DHPS genotyping was successful for 
all 15 pulmonary samples. A wild 
genotype was identifi ed in 9 samples, a 
165 mutant genotype in 1 sample, and 
a 171 mutant genotype in 2 samples. 
Mixed infections were identifi ed in the 
3 remaining samples.
Among the 15 room air samples, 
ITS genotyping was successful for 7; 
among these, 4 ITS genotypes were 
identifi ed (Table). Type Eg was again 
most frequently identifi ed. A mixed 
infection was detected in 1 of the 7 
samples. These results enabled us to 
compare ITS genotypes for 7 pairs 
of pulmonary and air samples. A full 
match was found for 4 (57.1%) pairs of 
samples, and a partial match, defi ned 
as at least 1 common genotype for 
pulmonary and air samples in mixed 
infections, was found for 2 (28.6%) 
pairs. No matches were found for the 
remaining pair of samples. DHPS 
genotyping was successful for 6 of 
the 15 air samples. A wild genotype 
was identifi ed in 4 samples, a 165 
mutant genotype was identifi ed in 1 
sample, and a 171 mutant genotype 
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Table. Genotyping of Pneumocystis jirovecii in pairs of pulmonary and air samples from 15 patients with Pneumocystis pneumonia* 
Patient no.† No. days between pulmonary 
and air sampling 
ITS genotype (no. sequenced clones)‡ DHPS genotype§ 
Pulmonary sample Air sample Pulmonary sample Air sample 
1 6 Gg, Fg (3)¶ ND Wild ND 
2 1 Ih (3) Eg (3) Wild ND 
4 0 Gg (3) Gg (3) Wild Wild 
5 0 Eg (3) Ec, Eg (3)¶ Wild Wild 
6 0 Eg (3) Eg (3) Mutant 171# Mutant 171 
7 1 Eg (3) ND Wild Wild 
8 0 Eg (2) Eg (1) Wild ND 
10 0 Eg (3) ND Mutant 171 ND 
11 0 Be, Ec (3¶) Ec (3) Mutant 165** Mutant 165 
13 2 Eg (3) ND Wild ND 
15 0 Eg, Fg (3)¶ ND Wild + mutant 171 ND 
16 0 Eg (3) ND Wild Wild 
17 1 Ie, Ih (2) ND Wild ND 
18 1 Bl (3) Bl (3) Wild + mutant 165 ND 
19 0 Eg, Bl (3¶) ND Wild + mutant 165 ND 
*ITS, internal transcribed spacers; DHPS, dihydropteroate synthase; ND, not determined. 
†Patients are numbered as described in (6). Pulmonary samples were bronchoalveloar lavage specimens for patients 2, 4, 6, 7, 8, 10, 11, 18, and 19 and 
induced sputum specimens for patients 1, 5, 13, 15, 16, and 17. 
‡P. jirovecii ITS genotype identification using sequence analysis with a prior cloning step and applying the score by Lee et al. (2).
§P. jirovecii DHPS genotype identification using a PCR restriction fragment length polymorphism assay (8).
¶Major ITS genotype, as identified in 2 of 3 clones. 
#Mutant genotype with the mutation at position 171. 
**Mutant genotype with the mutation at position 165. 
LETTERS
was identifi ed in 1 sample. These 
results enabled us to compare DHPS 
genotypes for 6 pairs of samples. A 
full match was found for these 6 pairs. 
DHPS and ITS genotype matches 
were found for 4 pairs.
Several lines of evidence 
suggest that P. jirovecii is exhaled 
by infected patients and transmitted 
by the airborne route to susceptible 
persons (4). In the study reported 
here, ITS or DHPS genotype matches 
between pairs of pulmonary and 
air samples are consistent with the 
possibility that P. jirovecii organisms 
in the air originated from patients. 
DHPS mutants were detected in 6 
(40%) of the 15 pulmonary samples; 
none of the15 patients had received 
sulfonamide treatment at the time of 
PCP diagnosis. These results were 
not unexpected because frequency of 
fi nding DHPS mutants in PCP patients 
in Paris who had no prior sulfonamide 
treatment is high (8). The exhalation of 
DHPS mutants from infected patients 
can spread potentially sulfonamide-
resistant organisms.
Matches of P. jirovecii genotypes 
in pairs of pulmonary and room air 
samples argue in favor of P. jirovecii 
exhalation by infected patients. The 
exhalation of P. jirovecii organisms 
emphasizes the risk for their 
nosocomial transmission. Our data 
provide additional arguments in favor 
of the application of measures to 
prevent the airborne transmission of P. 
jirovecii in hospitals.
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and Dengue Virus, 
Puerto Rico, 2010
To the Editor: Leptospirosis, 
caused by Leptospira spp. bacteria, 
and dengue, caused by dengue viruses 
(DENVs), are potentially fatal acute 
febrile illnesses (AFI) endemic 
to the tropics (1,2). Because their 
clinical manifestations are similar (3), 
leptospirosis may be misidentifi ed as 
dengue (4). We report a fatal case of 
co-infection with Leptospira spp. and 
DENV-1 in a man in Puerto Rico.
On May 23, 2010, a 42-year-old 
unemployed male carpenter came to 
an outpatient clinic in Puerto Rico 
reporting a 4-day history of fever, 
headache, generalized myalgia, 
anorexia, nausea, and vomiting. He was 
being treated for chronic hypertension 
and had been released from jail 2 weeks 
before illness onset. On evaluation, 
he was febrile, hypertensive, and 
tachycardic; laboratory results showed 
thrombocytopenia and leukocytosis 
with a predominance of neutrophils. 
Viral syndrome was diagnosed, and 
the patient was given acetaminophen, 
solumedrol, and ketoprofen.
The patient returned to the clinic on 
May 25 with continued fever, myalgia, 
worsening headache, and bilateral calf 
pain; he was afebrile and tachycardic 
and appeared acutely ill. He had no 
rash, jaundice, icteric sclera, cardiac 
murmurs, or organomegaly, and his 
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